Bosulif enters Phase III for Chronic Phase Philadelphia Chromosome Positive (Ph+) Chronic Myelogenous Leukemia (CML)

The Avillion Group announced that it has entered into an exclusive collaborative development agreement with Pfizer Inc. to conduct a global Phase III clinical trial of Pfizer's Bosulif (bosutinib). The trial, which will be conducted across multiple sites in the United States, Asia and Europe, will evaluate Bosulif, administered at a starting dose level of 400 mg daily, as a first-line treatment for patients with Chronic Phase Philadelphia Chromosome Positive (Ph+) Chronic Myelogenous Leukemia (CML)